Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It was approved in 2012 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Mogamulizumab